Loading...
Market
First non-COVID-19 disease targeted by self-amplifying RNA vaccine to receive approval by end of 2025?
2
Resolution / Starting Odds
Influenza • 25%
Zika Virus • 25%
HIV • 25%
Other • 25%
Regulatory announcements from health agencies such as the FDA, EMA, or equivalent
Story
EU to Approve U.S. Self-Amplifying RNA COVID-19 Vaccine Following Japan's Approval of ARCT-154 Self-Replicating mRNA
Dec 17, 2024, 02:23 PM
The European Union is set to approve a new self-amplifying RNA-based COVID-19 vaccine developed by a U.S. company. This follows Japan's recent approval of a similar self-replicating mRNA vaccine, ARCT-154, which allows the mRNA to replicate within cells. The advancements in mRNA technology, including the use of lipid nanoparticles (LNPs), are aimed at enhancing vaccine efficacy and targeting specific diseases. Researchers have also made progress in developing modified LNPs capable of crossing the blood-brain barrier, potentially enabling targeted therapies for brain and inflammatory diseases.
View original story
Similar markets
Influenza • 25%
Zika • 25%
HIV • 25%
Other • 25%
Influenza • 25%
Zika • 25%
HIV • 25%
Other • 25%
COVID-19 • 25%
Influenza • 25%
HIV • 25%
Other • 25%
Cancer • 25%
Diabetes • 25%
Autoimmune Disease • 25%
Other • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
Cancer immunotherapy • 25%
Influenza vaccine • 25%
HIV vaccine • 25%
Other • 25%
Cancer • 25%
Cardiovascular disease • 25%
Neurological disorder • 25%
Other • 25%
Cancer • 25%
Autoimmune disorders • 25%
Infectious diseases • 25%
Other • 25%
